Myrexis hands Azixa back to ever more desperate EpiCept
This article was originally published in Scrip
US oncology and pain company EpiCept has regained rights to Phase II cancer drug Azixa (verubulin), after biotech-turned-pharma-asset-hunter Salt Lake City-based Myrexis terminated its licence agreement with the company. EpiCept, which was already struggling to resolve its liquidity problem and to find a partner for its pain product AmiKet (amitriptyline and ketamine), is now searching for yet another partner.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.